Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
41 hedge funds and large institutions have $102M invested in Urovant Sciences Ltd. in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 10 closing their positions.
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
88% more capital invested
Capital invested by funds: $54.2M → $102M (+$47.4M)
78% more funds holding
Funds holding: 23 → 41 (+18)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.66% more ownership
Funds ownership: 18.72% → 19.39% (+0.66%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$9.3M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$4.36M |
| 3 |
PCM
Prelude Capital Management
New York
|
+$3.06M |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
+$2.99M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$9.14M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.31M |
| 4 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
-$4.92M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.47M |
UROV Hedge Fund Activity: Q4 2020 in Review
41 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q4 2020, worth a combined $102M — up 88% from $54.2M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new UROV positions and 10 closed out — a net gain of 18 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $9.3M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $9.14M sold.
- 41 institutional investors held Urovant Sciences Ltd. (UROV) as of Q4 2020, up from 23 in Q3 2020.
- Funds reported $102M of Urovant Sciences Ltd. stock for Q4 2020, up 88% quarter-over-quarter.
- 28 funds opened new Urovant Sciences Ltd. positions in Q4 2020 and 10 closed out, a net change of +18 holders.
- The largest Urovant Sciences Ltd. buyer in Q4 2020 was Perceptive Advisors, an estimated $9.3M added.
- The largest Urovant Sciences Ltd. seller in Q4 2020 was Baker Bros. Advisors, an estimated $9.14M sold.
Based on aggregated 13F filings for Q4 2020.